Plasma proteins were significantly associated with CT airway measures, including 2 proteins for lumen area (q=0.016), 3 for wall area (q=0.011), and 16 for percent wall area (q=0.002).
Case-Control (n=2,065)
Sí
Which plasma proteins and biological pathways are associated with CT measures of airway lumen and wall areas in adults with and without COPD?
Distinct plasma proteins and biological pathways are associated with CT airway measures of lumen area, wall area, and percent wall area, highlighting structural pathophysiologic features of COPD.
Abstract Rationale Chronic lower respiratory diseases (CLRD), including chronic obstructive pulmonary disease (COPD), were the third-leading causes of death globally in 2019. Quantitative computed tomography (CT) measures of airway wall and lumen areas are associated with greater respiratory symptoms, reduced FEV1, accelerated lung function decline, and higher risk of incident COPD. Even in individuals without COPD, greater airway wall thickness—corresponding to smaller absolute wall and lumen areas—predicts incident COPD and CLRD-related hospitalizations and mortality. Aims To identify protein signatures and biological pathways underlying airway lumen and wall areas using cross-sectional plasma protein associations with CT measures. Methods SPIROMICS is a multicenter longitudinal case-control study that recruited 2,983 adults with COPD and a 20+ packyear smoking history and controls aged 40-80 years between 2010-2015. Standardized chest CT scans were labeled with airway measures. A total of 1,255 plasma proteins measured by SomaScan were included. Linear regression models adjusted for demographic, clinical, and imaging covariates. Significance was defined by a False Discovery Rate (FDR) p-value (q-value) 0.05 using the Benjamini-Hochberg method. Replication was performed in two external cohorts with inverse variance-weighted meta-analysis. Proteins meeting nominal replication underwent elastic net regression and pathway enrichment (Gene Ontology GO and Reactome). Results Among 2,065 participants with CT and proteomic data (mean age 63.2 years, 46.3% women, 61.6% with COPD), proteins meeting replication were significantly associated with lumen area (2 proteins; top hit a disintegrin and metalloproteinase with thrombospondin motifs 5, q = 0.016), wall area (3 proteins; top hit leptin, q = 0.011), and percent wall area (16 proteins; top hit roundabout homolog 2, q = 0.002). Elastic net selected 2 proteins for lumen area, 3 for wall area, and 12 for percent wall area. Pathway enrichment revealed FDR-significant pathways only for percent wall area via GO (50 pathways; top hit axogenesis) and Reactome (1 pathway; diseases of glycosylation). Conclusions This study identified distinct proteins, signatures, and biological pathways associated with CT airway measures of lumen area, wall area, and percent wall area. Proteins linked to airway lumen and wall area are involved in metabolic and vasoactive processes, while those for percent wall area are involved in vascular remodeling, cell adhesion, and extracellular matrix organization—highlighting structural pathophysiologic features of COPD. These findings may inform biomarker discovery and prediction of disease onset and progression. This abstract is funded by: Funding: Daniel E. Guzman, MD, MSE was funded by T32-HL144442. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.
Guzman et al. (Fri,) conducted a case-control in COPD (n=2,065). Plasma proteins was evaluated on Association of plasma proteins with CT measures of airway lumen area, wall area, and percent wall area. Plasma proteins were significantly associated with CT airway measures, including 2 proteins for lumen area (q=0.016), 3 for wall area (q=0.011), and 16 for percent wall area (q=0.002).